Form D · Pharmaceuticals
IZUN PHARMACEUTICALS CORP
Jerusalem, L3 · CIK 0001406071
Offering snapshot reported Nov 13, 2014 · SEC filing
- Reported sold
- $1.12M Indefinite offering
- Investors reported
- 16 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Oct 31, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 13, 2014 | Initial | $1,120,006 | No comparison | 16 | SEC filing |
| Jun 19, 2012 | Initial | $4,083,045 | No comparison | 14 | SEC filing |
| Nov 26, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jul 6, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-228264
Source: Form D, filed Nov 13, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Citron | Executive |
| Hersch Cooper | Director |
| Elliot Hahn | Director |
| Benjamin Jesselson | Director |
| Jeremy Kon | Director |
| William Z Levine | Director, Executive |
| Yarom Oren | Director |
| Avner Rotman | Director |
| Aron Saffer | Director, Executive |
| Oscar Schafer | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
5 Kiryat Hamada Street Building 2
Jerusalem, L3, 91042
Jerusalem, L3, 91042